Clinical trial
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat…
NCT00418574 · Menarini Group, Industry · Terminated
Key facts
| NCT number | NCT00418574 |
|---|---|
| Title | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients |
| Official title | A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy |
| Acronym | MIMOSA |
| Lead sponsor | Menarini Group, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Biological |
| Interventions | Abagovomab, Placebo |
| Enrollment | 888 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Jan 5, 2007 |
| Last update posted | Nov 24, 2011 |
| Countries | Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: